Hypertrichosis is a condition of excessive hair growth in areas where hair is normally present but in amounts beyond expected for age, sex, and ethnicity. It can be congenital or acquired and may occur as an isolated finding or secondary to medications and systemic disorders. The pattern and distribution vary by subtype.
The FDA has accepted Regeneron's Biologics License Application for garetosmab to treat fibrodysplasia ossificans progressiva, granting Priority Review with a target action date of August 2026. The application is supported by Phase 3 OPTIMA trial data.
Soleno Therapeutics provided updates on its VYKAT XR commercial launch for Prader-Willi syndrome, reporting reimbursement progress across nearly 48 Medicaid programs and over 600 prescribers, while European regulatory review continues for approximately 9,500 additional patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05775328 |
Treatment of Hypertrichosis With Intense Pulsed Light |
RECRUITING | |
| NCT03273504 |
Efficacy Evaluation of the Activity of a Cosmetic Product (Topical Use) on Hair Regrowth vs Placebo |
COMPLETED | NA |
| NCT02793557 |
Investigation of FOL-005 on Clinical Safety and Effect on Hair Growth |
COMPLETED | PHASE1/PHASE2 |
| NCT02536092 |
A Prospective Multi-Center Study of a Novel Dual-Wavelength Laser for Hair Removal |
WITHDRAWN | NA |
| NCT01912950 |
Pilot Study of a Novel IPL for Removal of Unwanted Fine Body Hair |
COMPLETED | NA |
| NCT01212172 |
Comparison of Efficacy, Safety and Tolerability of Two Different 810 nm Diode Lasers for Hair Reduction |
COMPLETED | PHASE3 |
| NCT00773136 |
Eyelash Growth From Application of Bimatoprost in Gel Suspension to the Base of the Eyelashes |
COMPLETED | NA |
| NCT00580736 |
Optical Clearing of the Skin in Conjunction With Laser Treatments |
COMPLETED | PHASE1 |
| NCT00495443 |
Enhanced Safety Aesthetic Laser System |
UNKNOWN | NA |
| NCT00441948 |
Enhanced Safety Laser Hair Removal System |
UNKNOWN | NA |
